Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Treatment Clinical Trials for Exocrine Pancreas Carcinoma

Review the exocrine pancreas carcinoma treatment clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 162

The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer
Status: Active
Location: 297 locations
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib versus Placebo Following Curative Intent Therapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Status: Active
Location: 387 locations
Testing the Use of the Usual Chemotherapy before and after Surgery for Removable Pancreatic Cancer
Status: Active
Location: 338 locations
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
Status: Active
Location: 171 locations
A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)
Status: Active
Location: 24 locations
CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer
Status: Active
Location: 24 locations
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
Status: Active
Location: 22 locations
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Status: Active
Location: 20 locations
A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC
Status: Active
Location: 20 locations
A Study of 177Lu-FAP-2286 in Advanced Solid Tumors
Status: Active
Location: 17 locations
A Study of ASP3082 in Adults With Advanced Solid Tumors
Status: Active
Location: 17 locations
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Status: Active
Location: 17 locations
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
Status: Active
Location: 14 locations
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
Status: Active
Location: 13 locations
Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies
Status: Active
Location: 13 locations
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
Status: Active
Location: 10 locations
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Status: Active
Location: 10 locations
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Status: Active
Location: 9 locations
Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors
Status: Active
Location: 8 locations
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Status: Active
Location: 8 locations
A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
Status: Active
Location: 9 locations
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
Status: Active
Location: 9 locations
A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Status: Active
Location: 8 locations
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Status: Active
Location: 9 locations
Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC
Status: Active
Location: 7 locations